Syros Pharmaceuticals (NASDAQ:SYRS) Upgraded by StockNews.com to Hold

Syros Pharmaceuticals (NASDAQ:SYRSGet Rating) was upgraded by StockNews.com from a “sell” rating to a “hold” rating in a research note issued on Wednesday.

SYRS has been the topic of several other research reports. Zacks Investment Research downgraded Syros Pharmaceuticals from a “hold” rating to a “sell” rating in a research note on Friday, January 7th. Piper Sandler reduced their price target on Syros Pharmaceuticals from $18.00 to $10.00 in a report on Monday, January 10th. One equities research analyst has rated the stock with a sell rating, one has given a hold rating and three have issued a buy rating to the company. According to MarketBeat, the company presently has an average rating of “Hold” and a consensus price target of $14.60.

Shares of SYRS stock traded up $0.04 on Wednesday, reaching $0.99. 366,841 shares of the company’s stock were exchanged, compared to its average volume of 578,953. Syros Pharmaceuticals has a 52 week low of $0.91 and a 52 week high of $7.03. The company has a current ratio of 4.33, a quick ratio of 4.33 and a debt-to-equity ratio of 0.47. The stock has a market capitalization of $61.47 million, a PE ratio of -0.72 and a beta of 2.09. The company’s fifty day simple moving average is $1.26 and its 200 day simple moving average is $2.85.

Syros Pharmaceuticals (NASDAQ:SYRSGet Rating) last released its quarterly earnings results on Tuesday, March 15th. The company reported ($0.38) EPS for the quarter, topping the Thomson Reuters’ consensus estimate of ($0.43) by $0.05. Syros Pharmaceuticals had a negative return on equity of 75.67% and a negative net margin of 368.52%. During the same period last year, the business posted ($0.61) earnings per share. As a group, sell-side analysts predict that Syros Pharmaceuticals will post -1.83 earnings per share for the current fiscal year.

Hedge funds and other institutional investors have recently made changes to their positions in the company. LGT Capital Partners LTD. grew its holdings in shares of Syros Pharmaceuticals by 1,052.4% during the fourth quarter. LGT Capital Partners LTD. now owns 500,000 shares of the company’s stock worth $1,630,000 after purchasing an additional 456,612 shares during the last quarter. Connor Clark & Lunn Investment Management Ltd. lifted its position in shares of Syros Pharmaceuticals by 35.8% during the 3rd quarter. Connor Clark & Lunn Investment Management Ltd. now owns 103,307 shares of the company’s stock valued at $462,000 after acquiring an additional 27,255 shares during the period. Metropolitan Life Insurance Co NY acquired a new stake in shares of Syros Pharmaceuticals during the 3rd quarter valued at approximately $73,000. State Board of Administration of Florida Retirement System lifted its position in shares of Syros Pharmaceuticals by 233.0% during the 3rd quarter. State Board of Administration of Florida Retirement System now owns 78,535 shares of the company’s stock valued at $351,000 after acquiring an additional 54,950 shares during the period. Finally, SG Americas Securities LLC acquired a new position in shares of Syros Pharmaceuticals during the 3rd quarter worth approximately $139,000. Institutional investors and hedge funds own 81.27% of the company’s stock.

About Syros Pharmaceuticals (Get Rating)

Syros Pharmaceuticals, Inc, a biopharmaceutical company, focuses on the development of treatments for cancer and monogenic diseases, and building a pipeline of gene control medicines. The company's lead product candidates are Tamibarotene, a selective retinoic acid receptor alpha agonist, which is in Phase III clinical trial for genomically defined subset of patients with myelodysplastic syndrome and Phase II clinical trial for patients with acute myeloid leukemia; SY-2101, a novel oral form of arsenic trioxide for treating patients with acute promyelocytic leukemia; and SY-5609, a cyclin-dependent kinase 7 inhibitor, which is in a Phase I clinical trial in patients with select advanced solid tumors.

Featured Articles

Receive News & Ratings for Syros Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Syros Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.